Full video transcriptClick to expand
Auto-generated transcript of @qoob85's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00You know, how big can I get? How rip can I get? How strong can I get?
- 0:03I want to go to the max. I don't want people to say, wow, that's a nice pretty physique.
- 0:07I want people to say, what the fuck is that?
- 0:11That's what I wanted to do.
- 0:14Well, you succeeded.
Enclomiphene and MK-677 stacked: what the science says
Quick answer
The creator is self-administering a stack of enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone, alongside MK-677, an oral ghrelin mimetic that elevates growth hormone and IGF-1. Neither compound is FDA-approved for the purpose implied in the video, and their combined effects on insulin sensitivity, the hypothalamic-pituitary-gonadal axis, and cardiovascular markers in otherwise healthy men have not been studied in controlled trials. Without baseline labs and clinical monitoring, identifying adverse effects early is unlikely.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Enclomiphene and MK-677 stacked: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Enclomiphene and MK-677 stacked: what the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Enclomiphene and MK-677 stacked: what the science says" from damnqoob. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-administering a stack of enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone, alongside MK-677, an oral ghrelin mimetic that elevates growth hormone and IGF-1.
The reason this review is not generic is the source wording and the canonical claim label "peptides running my first cycle let s see how this goes nattyornot gy." In this clip, the useful excerpt is: "You know, how big can I get?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is self-administering a stack of enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone, alongside MK-677, an oral ghrelin mimetic that elevates growth hormone and IGF-1.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is self-administering a stack of enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone, alongside MK-677, an oral ghrelin mimetic that elevates growth hormone and IGF-1. Neither compound is FDA-approved for the purpose implied in the video, and their combined effects on insulin sensitivity, the hypothalamic-pituitary-gonadal axis, and cardiovascular markers in otherwise healthy men have not been studied in controlled trials. Without baseline labs and clinical monitoring, identifying adverse effects early is unlikely.
- Enclomiphene's most robust clinical data comes from hypogonadal men, not healthy men optimizing physique. Kim et al. (2013, Fertility and Sterility) found efficacy in secondary hypogonadism specifically.
- MK-677 raises GH and IGF-1 but also increases fasting glucose and insulin levels. Nass et al. (2008, JCEM) documented these metabolic trade-offs in a controlled 12-month trial.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Enclomiphene's most robust clinical data comes from hypogonadal men, not healthy men optimizing physique. Kim et al. (2013, Fertility and Sterility) found efficacy in secondary hypogonadism specifically.
- MK-677 raises GH and IGF-1 but also increases fasting glucose and insulin levels. Nass et al. (2008, JCEM) documented these metabolic trade-offs in a controlled 12-month trial.
- Androxal, the branded enclomiphene product, was rejected by the FDA in 2015 due to insufficient safety and efficacy data, meaning compounded enclomiphene has never completed the full regulatory review process.
- MK-677 appears on the WADA prohibited substances list under 'other anabolic agents' and is classified as a research chemical in the United States, not an approved therapeutic.
- The 'nattyplus' label has no clinical definition. Both compounds in this stack have direct endocrine effects and cannot be reasonably framed as natural or minimally intervening.
- Stacking an SERM with a ghrelin agonist simultaneously affects two major hormonal axes without published safety data for that specific combination in healthy men.
- Anyone self-administering either compound without baseline and follow-up labs for testosterone, estradiol, LH, FSH, IGF-1, and fasting glucose has no reliable way to detect adverse hormonal or metabolic changes early.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @qoob85 actually say?
Not much, technically. The transcript is almost entirely aesthetic ambition, not a pharmacological claim. The creator says they want to get so jacked that people say "what the fuck is that" rather than compliment a "pretty physique." The real information lives in the hashtags and caption: they're running a first cycle stacking enclomiphene with MK-677, framing it under the "nattyplus" umbrella that has become code for hormone-adjacent compounds that aren't classic anabolic steroids.
That framing matters. "Nattyplus" exists specifically to blur the line between natural and enhanced, and both enclomiphene and MK-677 sit squarely in enhanced territory. This video doesn't explain what either compound does, what doses are being used, what monitoring is in place, or what the risks are. It's a vibe check, not a health disclosure.
Does the science back this up?
The science on these two compounds is real but incomplete, and neither one is approved by the FDA for bodybuilding use. That's not a technicality, it's a meaningful gap in the evidence.
Enclomiphene is the trans-isomer of clomiphene citrate. It works by blocking estrogen receptors in the hypothalamus, which signals the pituitary to produce more LH and FSH, which in turn stimulates endogenous testosterone production. Kim et al. (2013, Fertility and Sterility) showed enclomiphene raised testosterone in men with secondary hypogonadism without suppressing spermatogenesis. That's a real effect. But the population studied was hypogonadal men under clinical supervision, not healthy young men chasing body composition goals.
MK-677 (ibutamoren) is a ghrelin receptor agonist that increases growth hormone and IGF-1 secretion. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) found it raised GH and IGF-1 levels in older adults but also increased fasting glucose and insulin resistance. It is not a SARM, not a peptide in the strict sense, and not approved for human use outside of trials.
What did they get wrong (or right)?
The creator didn't make specific pharmacological claims, so there's nothing factually wrong in the spoken words. The problem is what's implied and omitted.
Running enclomiphene in a healthy, presumably eugonadal young man is not the same as using it therapeutically. If testosterone is already normal, stimulating more LH and FSH may not produce the dramatic gains the "nattyplus" community suggests. The effect size for body composition in eugonadal men is not well-established in published literature.
MK-677 does raise GH pulse amplitude, and users often report improved sleep quality and appetite, but the appetite increase is significant. Weight gain from MK-677 frequently includes water retention and fat, not just lean mass. Calling this a clean physique compound is optimistic reading of the data.
Stacking both compounds also means two mechanisms affecting hormone axes simultaneously, with no publicly shared bloodwork, no physician oversight mentioned, and no acknowledgment of known side effects including elevated prolactin, insulin resistance, and potential suppression of the HPG axis over time.
What should you actually know?
Both compounds have real physiological effects and real risks that a 15-second TikTok with a catchphrase cannot cover.
- Enclomiphene is not FDA-approved for male hypogonadism as a standalone drug. Androxal, its branded form, failed to gain FDA approval in 2015 for reasons including incomplete safety data. Compounded enclomiphene is now widely available through telehealth, but compounded does not mean equivalent to a reviewed and approved drug.
- MK-677 is explicitly on the World Anti-Doping Agency prohibited list and is not approved for human use by the FDA. It is sold as a "research chemical," which is a legal workaround, not a safety guarantee.
- The "nattyplus" framing normalizes hormone manipulation in young men without the context that long-term effects on the HPG axis for healthy men using these compounds are genuinely unknown.
- Anyone considering either compound should have baseline bloodwork, including total testosterone, LH, FSH, estradiol, fasting glucose, and IGF-1, and should work with a licensed provider who can monitor changes over time.
Wanting an extreme physique is a legitimate goal. Pursuing it through unmonitored hormonal intervention is a gamble on your endocrine system that no TikTok comment section can help you troubleshoot.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
damnqoob · TikTok creator
1.5K views on this video
Running my first cycle let’s see how this goes 🙂↔️#nattyornot #gymtok #nattyplus #enclomiphene #mk677
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about enclomiphene's most robust clinical data comes from hypogonadal men, not?
Enclomiphene's most robust clinical data comes from hypogonadal men, not healthy men optimizing physique. Kim et al. (2013, Fertility and Sterility) found efficacy in secondary hypogonadism specifically.
What does the video say about mk-677 raises gh?
MK-677 raises GH and IGF-1 but also increases fasting glucose and insulin levels. Nass et al. (2008, JCEM) documented these metabolic trade-offs in a controlled 12-month trial.
What does the video say about androxal, the branded enclomiphene product, was rejected by the fda?
Androxal, the branded enclomiphene product, was rejected by the FDA in 2015 due to insufficient safety and efficacy data, meaning compounded enclomiphene has never completed the full regulatory review process.
What does the video say about mk-677 appears on the wada prohibited substances list under 'other?
MK-677 appears on the WADA prohibited substances list under 'other anabolic agents' and is classified as a research chemical in the United States, not an approved therapeutic.
What does the video say about the 'nattyplus' label has no clinical definition. both compounds in?
The 'nattyplus' label has no clinical definition. Both compounds in this stack have direct endocrine effects and cannot be reasonably framed as natural or minimally intervening.
What does the video say about stacking an serm with a ghrelin agonist simultaneously affects two?
Stacking an SERM with a ghrelin agonist simultaneously affects two major hormonal axes without published safety data for that specific combination in healthy men.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by damnqoob, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.